{"slideshow_credits": null, "snippet": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "abstract": "Catalyst Pharmaceuticals, Florida firm in competition for approval of drug that treats rare neuromuscular disorder called Lambert-Eaton myasthenic syndrome, has setback when FDA says it requires more information before approval is granted.", "section_name": "Health", "print_page": "5", "document_type": "article", "byline": {"person": [{"firstname": "Sabrina", "role": "reported", "lastname": "TAVERNISE", "rank": 1, "organization": ""}], "original": "By SABRINA TAVERNISE"}, "web_url": "http://www.nytimes.com/2016/02/18/health/fda-deals-setback-to-catalyst-in-race-for-drug-approval.html", "lead_paragraph": "Catalyst Pharmaceuticals, vying for exclusive rights to a drug that treats a rare neuromuscular condition, received a letter saying its application was incomplete.", "headline": {"main": "F.D.A. Deals Setback to Catalyst in Race for Drug Approval", "print_headline": "Drug Maker Dealt Setback in Race for F.D.A. Assent"}, "_id": "56c4c1e038f0d85d2735f49d", "word_count": "287", "multimedia": [], "pub_date": "2016-02-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "Catalyst Pharmaceutical Partners Inc", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Muscular Dystrophy", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Jacobus Pharmaceutical Co", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}